Upstream Bio presented additional analyses from its Phase 2 VIBRANT trial of verekitug at the American Academy of Allergy, Asthma & Immunology annual meeting in Philadelphia on March 1 2026. The worst‑observation‑carried‑forward analysis showed a placebo‑adjusted reduction in endoscopic nasal polyp score of –1.95 (p < 0.0001) and a reduction in patient‑reported nasal congestion score of –0.96 (p < 0.0001). These results confirm the positive top‑line data reported in September 2025 and reinforce the drug’s potential to reduce the need for surgery or systemic corticosteroids by 76 % (p = 0.03).
The data strengthen the case for verekitug as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). Consistency between the primary and WOCF analyses indicates that the observed benefit is robust even when accounting for rescue therapy use. A 76 % reduction in surgery or steroid use suggests a meaningful clinical benefit that could translate into a differentiated value proposition for patients and payers.
Chief medical officer Aaron Deykin highlighted the drug’s unique profile, noting that the presentation “continues to reinforce verekitug’s differentiated profile, comprising robust clinical activity with far less‑frequent dosing, relative to currently available biologics as a potential treatment of CRSwNP.” The every‑12‑week dosing schedule could improve adherence and reduce treatment burden compared with existing biologics that require more frequent administration.
Upstream Bio plans to initiate Phase 3 trials in CRSwNP and severe asthma. The positive Phase 2 data support the company’s strategy to advance the drug into pivotal studies, potentially accelerating regulatory submissions and market entry. The TSLP‑receptor targeting mechanism positions verekitug in a competitive landscape that includes dupilumab and tezepelumab, offering a distinct therapeutic approach.
The presentation underscores Upstream Bio’s progress toward a potentially transformative therapy for respiratory diseases. The robust efficacy signals, coupled with a convenient dosing schedule, could enhance the drug’s commercial prospects and strengthen the company’s pipeline as it moves toward Phase 3.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.